Xention Ltd.
🇬🇧United Kingdom
Bioequivalence Study of Capsule and Tablet Formulations of TA-8995
- First Posted Date
- 2015-08-14
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 26
- Registration Number
- NCT02523391
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
ADME Study in Healthy Male Subjects With TA-8995
- First Posted Date
- 2015-04-03
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 6
- Registration Number
- NCT02408055
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
Fed-Fasted, Single and Multiple Ascending Dose Trial of XEN-D0103
Phase 1
Completed
- Conditions
- Atrial Fibrillation
- Interventions
- Drug: PlaceboDrug: 10mg XEN-D0103Drug: 200mg XEN-D0103Drug: 30mg XEN-D0103Drug: 60mg XEN-D0103Drug: 120mg XEN-D0103Drug: 150mg XEN-D0103
- First Posted Date
- 2015-03-17
- Last Posted Date
- 2015-03-18
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 87
- Registration Number
- NCT02390258
- Locations
- 🇬🇧
ICON Development Solutions, Manchester, United Kingdom
Study of the Electrocardiographic Effects of TA-8995
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 136
- Registration Number
- NCT02241759
- Locations
- 🇬🇧
Covance Clinical Research Unit Ltd, Leeds, United Kingdom
A Study on the Effects of TA-8995 on Lp(a) in Subjects With Elevated Lp(a)
- First Posted Date
- 2014-09-16
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 42
- Registration Number
- NCT02241772
- Locations
- 🇩🇰
Herlev Hospital, Herlev, Denmark
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With COPD
Phase 2
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 27
- Registration Number
- NCT02233686
- Locations
- 🇬🇧
Medicines Evaluation Unit, Manchester, United Kingdom
A Study to Assess the Efficacy of XEN-D0501 in Reducing the Cough Frequency in Patients With Chronic Idiopathic Cough
- First Posted Date
- 2014-09-08
- Last Posted Date
- 2015-07-15
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT02233699
- Locations
- 🇮🇪
Belfast City Hospital, Belfast, Ireland
🇬🇧University Hospital of South Manchester, Manchester, United Kingdom
A Preliminary Drug Drug Interaction Study With TA-8995
Phase 1
Completed
- Conditions
- Pharmacokinetic Interactions
- Interventions
- First Posted Date
- 2014-04-28
- Last Posted Date
- 2016-10-03
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 18
- Registration Number
- NCT02124954
- Locations
- 🇬🇧
Covance, Leeds, United Kingdom
TA-8995: Its Use in Patients With Mild Dyslipidaemia (TULIP)
Phase 2
Completed
- Conditions
- Dyslipidemia
- Interventions
- First Posted Date
- 2013-10-28
- Last Posted Date
- 2014-08-21
- Lead Sponsor
- Xention Ltd
- Target Recruit Count
- 364
- Registration Number
- NCT01970215
- Locations
- 🇳🇱
Albert Schweitzer Ziekenhuis, Sliedrecht, Netherlands
🇳🇱Andromed Zoetermeer, Leiderdorp, Netherlands
🇳🇱Andromed Breda B.V, Breda, Netherlands
© Copyright 2025. All Rights Reserved by MedPath